dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pignolet, Beatrice |
dc.contributor.author | Rio Izquierdo, Jordi |
dc.contributor.author | Vermersch, Patrick |
dc.contributor.author | Ruet, Aurélie |
dc.contributor.author | deSèze, Jerome |
dc.contributor.author | Montalban Gairín, Xavier |
dc.contributor.author | Comabella Lopez, Manuel |
dc.contributor.author | Fissolo, Nicolás Miguel |
dc.date.accessioned | 2022-04-04T13:01:51Z |
dc.date.available | 2022-04-04T13:01:51Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Fissolo N, Pignolet B, Rio J, Vermersch P, Ruet A, deSèze J, et al. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. Neurol Neuroimmunol Neuroinflammation. 2021 Jul;8(4):e1003. |
dc.identifier.issn | 2332-7812 |
dc.identifier.uri | https://hdl.handle.net/11351/7293 |
dc.description | Natalizumab; Neurofilament sèric |
dc.language.iso | eng |
dc.publisher | Lippincott Williams & Wilkins |
dc.relation.ispartofseries | Neurology-Neuroimmunology & Neuroinflammation;8(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Filaments citoplasmàtics |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Neurofilament Proteins |
dc.subject.mesh | /blood |
dc.title | Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/NXI.0000000000001003 |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | proteínas de neurofilamentos |
dc.subject.decs | /sangre |
dc.relation.publishversion | https://doi.org/10.1212/NXI.0000000000001003 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Fissolo N, Comabella M] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Pignolet B] CRC-SEP Neurosciences Centre Hospitalier Universitaire Toulouse, CPTP INSERM UMR 1043 CNRS UMR 5282 et Université de Toulouse III, UPS, France. [Rio J, Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Vermersch P] Univ. Lille, Inserm U1172, CHU Lille, FHU Imminent, France. [Ruet A] CHU de Bordeaux, INSERM-CHU CIC-P 0005, Service de Neurologie, Bordeaux F-33076, France. Université de Bordeaux, Bordeaux F-33076, France. [deSèze J] Department of Neurology, Hôpital Civil, Strasbourg |
dc.identifier.pmid | 33903203 |
dc.identifier.wos | 000711800300019 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |